Armata Pharmaceuticals, Inc.宣布，其创新药物AP-SA02已获得美国食品药品监督管理局（FDA）颁发的合格传染病产品（QIDP）认定。这一重要监管里程碑将有助于加速该候选药物的开发进程。
Armata Pharmaceuticals, Inc.宣布，其创新药物AP-SA02已获得美国食品药品监督管理局（FDA）颁发的合格传染病产品（QIDP）认定。这一重要监管里程碑将有助于加速该候选药物的开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.